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extracted from a UK primary care database (The Health
Improvement Network). Patients were required to have at least
12 months of data before and after switching. The principle
analysis was the change in HbA1c; secondary analyses included
change in weight and insulin dose. Hypoglycaemia could not be
assessed due to inconsistency in the recording of episodes. Mul-
tivariate analyses were used to adjust for baseline characteristics
and confounding variables. RESULTS: Mean HbA1c levels at
baseline were similar in the T1 and T2 cohorts (8.8% and 8.9%
respectively). After adjustment, both diabetic cohorts showed
statistically signiﬁcant reductions in mean HbA1c 12 months after
switch, by 0.38% (p < 0.001) in T1 and 0.31% (p < 0.001) in T2
patients. Improvement in HbA1c was positively correlated with
baseline HbA1c; patients with baseline HbA1c  8% had reduc-
tions of 0.57% (p < 0.001) and 0.47% (p < 0.001), respectively.
There was no signiﬁcant change in weight or total daily insulin
dose while on glargine. The majority of patients received a basal-
bolus regimen prior to and after switch (mean 79.3% before and
77.2% after switch in T1 patients and 80.4% and 76.8%, respec-
tively in T2 patients, p > 0.05). CONCLUSIONS: In routine
clinical practice, switching from NPH to glargine provides the
opportunity for improving glycaemic control in diabetes patients
inadequately controlled by NPH.
PDB3
SWITCHING FROM PREMIXED INSULINTO INSULIN
GLARGINE-BASED REGIMEN IMPROVES GLYCAEMIC
CONTROL IN PATIENTS WITHTYPE 1 ORTYPE 2 DIABETES:
A RETROSPECTIVE PRIMARY CARE-BASED ANALYSIS
McEwan P1, Gordon JP1, Sharplin P1, Longman AJ1, Peters J2,
Tetlow AP1
1Cardiff Research Consortium, Cardiff, UK, 2Cardiff University, Cardiff,
UK
OBJECTIVES: To investigate the effect on glycaemic control of
switching from a premix-based regimen to a glargine-based
regimen in 528 patients with type 1 (n = 183) or type 2 (n = 345)
diabetes, using unselected primary care data from a UK database
(The Health Improvement Network). METHODS: Patients were
required to have at least 12 months of available data, before and
after switching. The principle analysis was the change in HbA1c;
secondary analyses included change in weight, bolus usage and
insulin dose. Hypoglycaemia could not be assessed due to lack of
consistency in the recording of episodes. Multivariate analyses
were used to adjust for baseline characteristics and confounding
variables. RESULTS: Mean HbA1c levels at baseline were similar
in the T1 and T2 cohorts (9.4% and 9.3% respectively). After
adjustment both cohorts showed signiﬁcant reduction in mean
HbA1c 12 months after the switch: by -0.67% (p < 0.001) in the
T1 cohort and by -0.53% (p < 0.001) in the T2 cohort. Patients
with a baseline HbA1c  10% had the greatest reduction in
HbA1c, by -1.7% (p < 0.001) and -1.2% (p < 0.001), respec-
tively. Proportion of patients receiving a co-bolus prescription
went from 24.6% on premix to 95.1% on glargine in the T1
cohort, p < 0.001 and from 16.2% to 73.9% in the T2 cohort,
p < 0.001. There was no signiﬁcant change in weight in the T2
cohort with a moderate increase in T1 patients (0.3 kg and 3.7 kg
respectively, p > 0.05). Total insulin use (SD) increased in T2
patients (0.67  1.35 IU/Kg to 0.88  1.33 IU/Kg, p < 0.001)
with no signiﬁcant increase in T1 diabetes patients. CONCLU-
SIONS: In everyday practice, patients with T1 or T2 diabetes
inadequately controlled by premix insulins experienced signiﬁ-
cant improvement in glycaemic control over 12 months after
switching to a glargine-based regimen. These ﬁndings support the
use of glargine plus boluses in patients poorly controlled on
premix.
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OBJECTIVES: The control of blood glucose improves the long
term outcomes for patients with type 2 diabetes; this study exam-
ined the levels of glycemic control in a clinic at MSFHCC, Saudi
Arabia. METHODS: Data were obtained from patient medical
records. All patients who met the inclusion criteria: (with type 2
diabetes, made at least four visits during one year, had their
glycated hemoglobin (A1c) level been checked), the time frame
for sampling is 18 months ending in December 2007. Descriptive
statistics, logistics regression, and ANOVA were used in the
analysis. RESULTS: Four hundred nine patients’ records met the
inclusion criteria, male are 64.7% of the sample, the means for
age, A1c, BMI, and the duration of the DM were 53.4, 8.3%,
30.6 and 9.3 years, respectively. A total of 24.9% of the sample
has A1c at the target control level (<7%), the test of differences
of means of age, BMI and Duration of having DM across the
levels of A1c (controlled , not well controlled (7%  A1c < 8.5),
and poorly controlled (A1c  8.5)) did show consistent results
except BMI variable, group at the controlled HbA1c level has
signiﬁcant higher BMI means than the group with poorly con-
trolled A1c level. 13.2% of the sample treated with oral mono-
therapy antidiabetic drugs, 25.6% with a combination of Insulin
and Metformin, and the rest were with multitherapy. In the
logistic regression model, the type of therapy and the duration of
diabetes were signiﬁcant predictors for whether patient has con-
trolled A1c level. CONCLUSIONS: The high rate of uncon-
trolled diabetic patients is an evidence of shortcoming. Large
data might provide much and precise information to explain this
high rate. The unexpected relationship between BMI and A1c
level which noticed in controlled group could be explained by
short duration of diabetes, early aggressive therapy regimens or
other pathophysiological factors. Further follow up of such con-
trolled group may provide an explanation of such relationship.
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OBJECTIVES: We examined glycemic outcomes in patients with
type 2 diabetes (T2D) initiated to insulin glargine (GLAR) or
detemir (DET) using electronic medical records (EMR) from a
specialty practice in Baltimore, US. METHODS: Patients’ EMRs
using GLAR (n = 134) or DET (n = 88) between January 2005–
2007 with at least 4 available clinic visits were evaluated. Each
patient on DET was matched with one or more patients on
GLAR by baseline HbA1c. Average follow-up time was 6 months
RESULTS: Patients were similar in age (59 vs 60 years), HbA1c
(8.65 vs 8.46%), and BMI (33.6 vs 33.7 kg/m2) but differed in
T2D duration (12.9 vs 10years, P = 0.03) and gender (female 58
vs 44%, P = 0.04) between GLAR and DET, respectively. Prior
use of antidiabetic drugs was similar except for a higher percent-
age of patients using premixed insulin in GLAR (24.8% vs 8.9%
[DET], P = 0.004) and of patients using exenatide in DET
(32.9% vs 6.2 % [GLAR], P = 0.0001). Unadjusted A1C values
A496 Abstracts
